Alicia Morgans discusses key take home messages from the prostate cancer presentations from ASCO GU 2019 with Edward Schaeffer.  He highlighted presentations on the diagnosis and treatment of prostate cancer across the disease continuum, developing tools for shared decision making between the physican and patient, the pros and cons of screening for prostate cancer and both the ARAMIS and the ARCHES trial results.

Biographies:

Edward Schaeffer, MD, Ph.D. is Chair of the Department of Urology at Feinberg School of Medicine and Program Director of the Genitourinary Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Dr. Schaeffer is an Edmund Andrews Professor of Urology and his clinical and research focus is the diagnosis and treatment of men with prostate cancer.

Alicia Morgans, MD, MPH Associate Professor of Medicine in the Division of Hematology/Oncology at the Northwestern University Feinberg School of Medicine in Chicago, Illinois.

Related Content:

Oligometastatic Disease: Tumor Board - A Urologic Oncologist Perspective by Edward Schaeffer, MD

Oligometastatic Disease: Tumor Board - A Medical Oncologist Perspective by Michael Morris, MD

Assessment of Circulating Tumor Cell Number as a Transitional Surrogate Endpoint for Survival in Phase II Trials for Metastatic Castrate-Resistant Prostate Cancer

ARAMIS: Efficacy and Safety of Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer

ARCHES Trial-Phase 3 Study of ADT with Enzalutamide in mHSPC